nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

05.04.2018 | Original Article – Clinical Oncology

Is tumor volume reduction during radiotherapy prognostic relevant in patients with stage III non-small cell lung cancer?

verfasst von: Khaled Elsayad, Laith Samhouri, Sergiu Scobioala, Uwe Haverkamp, Hans Theodor Eich

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose/objective(s)

Lung cancer tumor volume reduction is common during radiation treatment (RT). The purpose of this study was to investigate tumor volume reduction ratio (VRR) and its correlation with outcomes in a cohort of patients with stage III non-small cell lung cancer (NSCLC) who underwent image-guided radiochemotherapy (RCTx).

Materials/methods

Fifty patients with NSCLC treated with fractionated RT at our institution between 2013 and 2017 were included. The relationship between gross tumor volume (GTV) changes during RT (week 1 vs. week 5) and outcomes were evaluated.

Results

The median radiation dose delivered was 59.4 Gy (median fraction dose, 1.8 Gy). The median GTV before treatment was 119 cm³, with a median GTV change of − 40%. Patients with more volume reduction had poorer tumor control. A VRR > 40% was associated with a poorer OS and PFS in patients with non-adenocarcinoma (non-ADC) histology. In multivariate analysis, VRR during RT, and chemotherapy (CTx) administration remained related to PFS and OS, while initial GTV remained a significant determinant for OS. In subgroup analyses, and CTx (p = 0.038) affected PFS among non-ADC patients, with initial GTV (p = 0.058) and VRR (p = 0.08) showing non-significant trends. Initial GTV (p = 0.023), VRR (p = 0.038), and CTx (p = 0.01) remained significant predictors for OS in the non-ADC group.

Conclusion

Worse tumor control and OS in non-ADC patients are observed with more marked RT-induced tumor shrinkage, supporting the development of response-adaptive treatment strategies, particularly in non-ADC NSCLC patients.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, Wit M de, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y-C, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, Castro Carpeño J de, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929. https://doi.org/10.1056/NEJMoa1709937 CrossRefPubMed

Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:187–199. https://doi.org/10.1016/S1470-2045(14)71207-0 CrossRefPubMedPubMedCentral

Bral S, Ridder M de, Duchateau M, Gevaert T, Engels B, Schallier D, Storme G (2011) Daily megavoltage computed tomography in lung cancer radiotherapy: correlation between volumetric changes and local outcome. Int J Radiat Oncol Biol Phys 80:1338–1342. https://doi.org/10.1016/j.ijrobp.2010.04.002 CrossRefPubMed

Brierley J, Gospodarowicz MK, Wittekind C (eds) (2017) TNM classification of malignant tumours, 8th edn. Wiley-Blackwell. ISBN: 978-1-119-26357-9

Brink C, Bernchou U, Bertelsen A, Hansen O, Schytte T, Bentzen SM (2014) Locoregional control of non-small cell lung cancer in relation to automated early assessment of tumor regression on cone beam computed tomography. Int J Radiat Oncol Biol Phys 89:916–923. https://doi.org/10.1016/j.ijrobp.2014.03.038 CrossRefPubMed

Chan MKH, Werner R, Ayadi M, Blanck O (2015) Comparison of 3D and 4D Monte Carlo optimization in robotic tracking stereotactic body radiotherapy of lung cancer. Strahlenther Onkol 191:161–171. https://doi.org/10.1007/s00066-014-0747-5 CrossRefPubMed

Chi A, Nguyen NP, Welsh JS, Tse W, Monga M, Oduntan O, Almubarak M, Rogers J, Remick SC, Gius D (2014) Strategies of dose escalation in the treatment of locally advanced non-small cell lung cancer: image guidance and beyond. Front Oncol 4:156. https://doi.org/10.3389/fonc.2014.00156 PubMedPubMedCentral

Eberhardt WEE, Poettgen C, Gauler TC, Friedel G, Veit S, Heinrich V, Welter S, Budach W, Spengler W, Kimmich M, Fischer B, Schmidberger H, Ruysscher D de, Belka C, Cordes S, Hepp R, Luetke-Brintrup D, Lehmann N, Schuler M, Joeckel K-H, Stamatis G, Stuschke M (2015) Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB Non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol 33:4194–4201. https://doi.org/10.1200/JCO.2015.62.6812 CrossRefPubMed

Elsayad K, Kriz J, Reinartz G, Scobioala S, Ernst I, Haverkamp U, Eich HT (2016) Cone-beam CT-guided radiotherapy in the management of lung cancer: diagnostic and therapeutic value. Strahlenther Onkol 192:83–91. https://doi.org/10.1007/s00066-015-0927-y CrossRefPubMed

Guckenberger M, Richter A, Wilbert J, Flentje M, Partridge M (2011a) Adaptive radiotherapy for locally advanced non–small-cell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control. Int J Radiat Oncol Biol Phys 81:e275–e282. https://doi.org/10.1016/j.ijrobp.2011.01.067 CrossRefPubMed

Guckenberger M, Wilbert J, Richter A, Baier K, Flentje M (2011b) Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced non–small cell lung cancer. Int J Radiat Oncol Biol Phys 79:901–908. https://doi.org/10.1016/j.ijrobp.2010.04.050 CrossRefPubMed

Guckenberger M, Kavanagh A, Partridge M (2012) Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer. Strahlenther Onkol 188:894–900. https://doi.org/10.1007/s00066-012-0161-9 CrossRefPubMed

Houston KA, Henley SJ, Li J, White MC, Richards TB (2014) Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004–2009. Lung Cancer 86:22–28. https://doi.org/10.1016/j.lungcan.2014.08.001 CrossRefPubMedPubMedCentral

Jabbour SK, Kim S, Haider SA, Xu X, Wu A, Surakanti S, Aisner J, Langenfeld J, Yue NJ, Haffty BG, Zou W (2015) Reduction in tumor volume by cone beam computed tomography predicts overall survival in non-small cell lung cancer treated with chemoradiation therapy. Int J Radiat Oncol Biol Phys 92:627–633. https://doi.org/10.1016/j.ijrobp.2015.02.017 CrossRefPubMedPubMedCentral

Jeremic B (2015) Standard treatment option in stage III non-small-cell lung cancer: case against trimodal therapy and consolidation drug therapy. Clin Lung Cancer 16:80–85. https://doi.org/10.1016/j.cllc.2014.08.003 CrossRefPubMed

Kanzaki H, Kataoka M, Nishikawa A, Uwatsu K, Nagasaki K, Nishijima N, Ochi T, Mochizuki T (2016) Impact of early tumor reduction on outcome differs by histological subtype in stage III non-small-cell lung cancer treated with definitive radiotherapy. Int J Clin Oncol 21:853–861. https://doi.org/10.1007/s10147-016-0982-0 CrossRefPubMed

Käsmann L, Niyazi M, Blanck O, Baues C, Baumann R, Dobiasch S, Eze C, Fleischmann D, Gauer T, Giordano FA, Goy Y, Hausmann J, Henkenberens C, Kaul D, Klook L, Krug D, Mäurer M, Panje CM, Rosenbrock J, Sautter L, Schmitt D, Süß C, Thieme AH, Trommer-Nestler M, Ziegler S, Ebert N, Medenwald D, Ostheimer C (2017) Prädiktiver und prognostischer Wert des tumorvolumens und seiner veränderungen während radikaler strahlentherapie beim nicht-kleinzelligen bronchialkarzinom im stadium III: ein systematischer review (predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage iii non-small cell lung cancer: a systematic review). Strahlenther Onkol. https://doi.org/10.1007/s00066-017-1221-y

Koo TR, Moon SH, Lim YJ, Kim JY, Kim Y, Kim TH, Cho KH, Han J-Y, Lee YJ, Yun T, Kim HT, Lee JS (2014) The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. Radiat Oncol 9:2692. https://doi.org/10.1186/s13014-014-0283-6 CrossRef

Kwint M, Conijn S, Schaake E, Knegjens J, Rossi M, Remeijer P, Sonke J-J, Belderbos J (2014) Intra thoracic anatomical changes in lung cancer patients during the course of radiotherapy. Radiother Oncol 113:392–397. https://doi.org/10.1016/j.radonc.2014.10.009 CrossRefPubMed

Li R, Han B, Meng B, Maxim PG, Xing L, Koong AC, Diehn M, Loo BW (2013) Clinical implementation of intrafraction cone beam computed tomography imaging during lung tumor stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys 87:917–923. https://doi.org/10.1016/j.ijrobp.2013.08.015 CrossRefPubMedPubMedCentral

Ostheimer C, Schweyer F, Reese T, Bache M, Vordermark D (2016) The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small cell lung cancer. Oncol Lett 12:3449–3456. https://doi.org/10.3892/ol.2016.5104 CrossRefPubMedPubMedCentral

Ostheimer C, Baues C, Baumann R, Dobiasch S, Eze C, Fleischmann D, Gauer T, Giordano FA, Goy Y, Hausmann J, Henkenberens C, Kaul DP, Kloock L, Krug D, Kaesmann L, Niyazi K-M, Maeurer M, Oertel M, Panje C, Rosenbrock J, Sautter L, Schmitt D, Suess C, Thieme AH, Trommer-Nestler M, Ziegler S, Ebert N, Medenwald D (2018) Prognostic relevance of tumor volume and its changes in the radical radiotherapy of advanced NSCLC—a multicenter retrospective evaluation of the working group “young DEGRO” of the German Society of Radiation Oncology (DEGRO). Oncol Res Treat 41:106

Peeken JC, Nüsslin F, Combs SE (2017) Radio-oncomics: das potenzial von radiomics in der strahlenonkologie (“radio-oncomics”: the potential of radiomics in radiation oncology). Strahlenther Onkol 193:767–779. https://doi.org/10.1007/s00066-017-1175-0 CrossRefPubMed

Rodrigues G, Choy H, Bradley J, Rosenzweig KE, Bogart J, Curran WJ, Gore E, Langer C, Louie AV, Lutz S, Machtay M, Puri V, Werner-Wasik M, Videtic GMM (2015) Definitive radiation therapy in locally advanced non-small cell lung cancer: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol 5:141–148. https://doi.org/10.1016/j.prro.2015.02.012 CrossRefPubMed

Roengvoraphoj O, Wijaya C, Eze C, Li M, Dantes M, Taugner J, Tufman A, Huber RM, Belka C, Manapov F (2017) Analyse des metabolischen primärtumorvolumens im verlauf der radiochemotherapie bei lokal fortgeschrittenem nichtkleinzelligem lungenkarzinom (analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer). Strahlenther Onkol. https://doi.org/10.1007/s00066-017-1229-3

Semrau S, Zettl H, Hildebrandt G, Klautke G, Fietkau R (2014) Older patients with inoperable non-small cell lung cancer: long-term survival after concurrent chemoradiotherapy. Strahlenther Onkol 190:1125–1132. https://doi.org/10.1007/s00066-014-0710-5 CrossRefPubMed

Siker ML, Tome WA, Mehta MP (2006) Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy: how reliable, consistent, and meaningful is the effect? Int J Radiat Oncol Biol Phys 66:135–141. https://doi.org/10.1016/j.ijrobp.2006.03.064 CrossRefPubMed

Tvilum M, Khalil AA, Møller DS, Hoffmann L, Knap MM (2015) Clinical outcome of image-guided adaptive radiotherapy in the treatment of lung cancer patients. Acta Oncol 54:1430–1437. https://doi.org/10.3109/0284186X.2015.1062544 CrossRefPubMed

Wanet M, Delor A, Hanin F-X, Ghaye B, van Maanen A, Remouchamps V, Clermont C, Goossens S, Lee JA, Janssens G, Bol A, Geets X (2017) Studie zur individualisierten bestrahlungsdosiseskalation bei nichtkleinzelligem lungenkarzinom basierend auf der FDG-PET-bildgebung (an individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging). Strahlenther Onkol 193:812–822. https://doi.org/10.1007/s00066-017-1168-z CrossRefPubMed

Titel: Is tumor volume reduction during radiotherapy prognostic relevant in patients with stage III non-small cell lung cancer?
verfasst von: Khaled Elsayad
Laith Samhouri
Sergiu Scobioala
Uwe Haverkamp
Hans Theodor Eich
Publikationsdatum: 05.04.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2640-6

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Is tumor volume reduction during radiotherapy prognostic relevant in patients with stage III non-small cell lung cancer?

Abstract

Purpose/objective(s)

Materials/methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose/objective(s)

Materials/methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Ovarian metastasis in patients with endometrial cancer: risk factors and impact on survival

High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma

Impact of peri-operative blood transfusion on post-operative infections after radical gastrectomy for gastric cancer: a propensity score matching analysis focusing on the timing, amount of transfusion and role of leukocyte depletion

Quality control and improvement of cancer care: what is needed? 4th European Roundtable Meeting (ERTM) May 5th, 2017, Berlin, Germany

Cartilage oligomeric matrix protein is a prognostic factor and biomarker of colon cancer and promotes cell proliferation by activating the Akt pathway

Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie